ストックスクリーナーアプリを入手
3.73
0.27%
0.010
前日終値:
$3.72
開ける：
$3.72
24時間の取引高:
1.85M
Relative Volume:
1.31
時価総額：
$1.27B
収益：
$787.89M
当期純損益:
$20.56M
株価収益率:
63.76
EPS:
0.0585
ネットキャッシュフロー:
$96.54M
1週間 パフォーマンス:
+1.36%
1か月 パフォーマンス:
+23.92%
6か月 パフォーマンス:
+71.10%
1年 パフォーマンス:
+5.37%
1日の値動き範囲:
$3.635
$3.75
1週間の範囲:
$3.54
$3.89
52週間の値動き範囲:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
名前
Goodrx Holdings Inc
セクター
電話
(855) 268-2822
住所
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, TXG
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.73 | 1.22B | 787.89M | 20.56M | 96.54M | 0.0585 |
VEEV
Veeva Systems Inc
|
243.75 | 39.23B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.71 | 11.81B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
52.10 | 9.85B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
104.73 | 8.82B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
56.09 | 7.52B | 638.78M | -22.66M | 122.18M | -0.1744 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2026-01-22 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-08-11 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 開始されました | Mizuho | Neutral |
| 2024-08-09 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 開始されました | Leerink Partners | Outperform |
| 2024-01-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-08-10 | アップグレード | DA Davidson | Neutral → Buy |
| 2023-07-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 開始されました | Citigroup | Buy |
| 2022-11-04 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-08-12 | 開始されました | DA Davidson | Neutral |
| 2022-06-10 | ダウングレード | Goldman | Buy → Neutral |
| 2022-06-06 | 再開されました | BofA Securities | Buy |
| 2022-06-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-05-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 開始されました | Wells Fargo | Equal Weight |
| 2022-04-07 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Neutral |
| 2022-03-15 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 繰り返されました | Barclays | Overweight |
| 2022-03-01 | 繰り返されました | BofA Securities | Neutral |
| 2022-03-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-03-01 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 繰り返されました | Evercore ISI | Outperform |
| 2022-03-01 | 繰り返されました | Goldman | Buy |
| 2022-03-01 | 繰り返されました | JP Morgan | Underweight |
| 2022-03-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-03-01 | 繰り返されました | SVB Leerink | Outperform |
| 2022-01-07 | 開始されました | Goldman | Buy |
| 2021-12-21 | 開始されました | Stephens | Overweight |
| 2021-12-02 | 開始されました | Jefferies | Buy |
| 2021-08-31 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-08-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 開始されました | Robert W. Baird | Neutral |
| 2021-04-06 | 再開されました | Evercore ISI | Outperform |
| 2021-01-25 | 開始されました | Guggenheim | Buy |
| 2020-11-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 開始されました | Barclays | Equal Weight |
| 2020-10-19 | 開始されました | BofA Securities | Neutral |
| 2020-10-19 | 開始されました | Citigroup | Buy |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-10-19 | 開始されました | Credit Suisse | Outperform |
| 2020-10-19 | 開始されました | Deutsche Bank | Hold |
| 2020-10-19 | 開始されました | Goldman | Neutral |
| 2020-10-19 | 開始されました | JP Morgan | Neutral |
| 2020-10-19 | 開始されました | Morgan Stanley | Overweight |
| 2020-10-19 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 開始されました | SVB Leerink | Outperform |
| 2020-10-19 | 開始されました | UBS | Buy |
すべてを表示
Goodrx Holdings Inc (GDRX) 最新ニュース
GoodRx (GDRX) Q2 2026 Earnings Call Transcript - aol.com
GoodRx (NASDAQ:GDRX) Rating Increased to Buy at Wall Street Zen - marketbeat.com
Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX) - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - marketbeat.com
GDRX Maintained by UBS -- Price Target Raised to $3.75 - GuruFocus
GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook - Yahoo Finance
GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise - Yahoo Finance
GoodRx (NASDAQ:GDRX) Trading Down 5.1%What's Next? - marketbeat.com
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope (NASDAQ:GDRX) - Seeking Alpha
Why Is GoodRx Holdings (GDRX) Putting Finance And Strategy Under Justin Fengler? - Sahm
GDRX Maintained by Citigroup -- Price Target Raised to $5.00 - GuruFocus
GoodRx (NASDAQ:GDRX) Stock Price Expected to Rise, Citigroup Analyst Says - marketbeat.com
GDRX Maintained by TD Cowen -- Price Target Raised to $5.00 - GuruFocus
GDRX Q2 Deep Dive: Pharma Direct and Subscription Growth Drive Upgraded Outlook - Yahoo Finance UK
GOODRX HOLDINGS, INC. : CITIGROUP RAISES TARGET PRICE TO $5 FROM $4 - Bitget
GDRX Maintains Overweight by Wells Fargo -- Price Target Raised to $5.00 - GuruFocus
GoodRx Holdings Price Target Raised to $5.00/Share From $3.50 by Wells Fargo - Moomoo
Prescription savings giant GoodRx could be opening office at The Pearl - The Business Journals
GoodRx Holdings Inc (GDRX) Stock Analysis & Forecast - TradingKey
GoodRx Holdings Inc (GDRX) Stock News Today - TradingKey
Wells Fargo & Company Boosts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - MarketBeat
GoodRx Holdings Inc (GDRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.7 - TradingView
Morgan Stanley Adjusts Price Target on GoodRx to $4 From $3, Maintains Equalweight Rating - marketscreener.com
Earnings call transcript: GoodRx lifts 2026 outlook after Q2 revenue beat - Investing.com Canada
Transcript : GoodRx Holdings, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
GoodRx Lets Customers Shop Where They Want, CEO Says - marketscreener.com
GoodRx Q2 Earnings Call Highlights - marketbeat.com
GoodRx (NASDAQ:GDRX) Stock Price Up 15.7%Here's Why - MarketBeat
GDRX: Pharma Direct and subscriptions drove Q2 outperformance, leading to raised 2026 guidance - TradingView
GoodRx Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
GDRX Looks 42.2% Undervalued on GF Value™ - GuruFocus
GDRX SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
GoodRx (NASDAQ:GDRX) Posts Earnings Results, Hits Estimates - MarketBeat
GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates - Yahoo Finance
GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Is GoodRx Holdings Inc (GDRX) Undervalued After Q2 Earnings? EPS - GuruFocus
GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars - Barchart.com
GoodRx Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aug 05 (Reuters)GoodRx Holdings Q2 Revenue - Moomoo
GDRX: Pharma Direct and subscription growth drove raised 2026 guidance despite lower transactions - tradingview.com
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q2 EPS; Offers Guidance - StreetInsider
GoodRx Reports Second Quarter 2026 Results - marketscreener.com
GoodRx Holdings, Inc. 2026: Revenue $200.41M, EPS $0.02— 10-Q Summary - TradingView
GoodRx Holdings (NASDAQ: GDRX) elevates Justin Fengler to CFO role - stocktitan.net
GoodRx Holdings (NASDAQ: GDRX) pivots as Rx revenue falls 26% - Stock Titan
GoodRx Holdings, Inc. Announces Management Changes - marketscreener.com
GoodRx Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GoodRx (NASDAQ: GDRX) Q2 2026 revenue hits $200M as mix shifts - Stock Titan
BRIEF-GoodRx Holdings Q2 Adjusted Net Income USD 26.8 Million Vs. IBES Estimate USD 27.2 Million - TradingView
GoodRx Holdings, Inc. Raises Earnings Guidance for the Year 2026 - marketscreener.com
Goodrx Holdings Inc (GDRX) 財務データ
収益
当期純利益
現金流量
EPS
Goodrx Holdings Inc (GDRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
1.10%
6.73%
大文字化:
|
ボリューム (24 時間):